Abstract
Infliximab, a chimeric monoclonal antibody that binds the tumor necrosis factor α (TNFα), is used in the treatment of rheumatoid arthritis (RA) and Crohn’s disease (CD). Previous cases of significant secondary liver disease associated with infliximab treatment have been reported in patients with RA, CD, and psoriatic arthritis. Two additional patients with RA who developed a serious liver disease associated with infliximab treatment are reported here. A 39-year old RA patient was admitted with cholestatic liver disease after 8 months of treatment with infliximab. She had no history of hepatic diseases, exposure to hepatotoxic or illicit drugs, or alcohol abuse. A liver biopsy showed severe ductal proliferation with collapse and enucleation of the hepatocytes. Despite aggressive treatment with oral prednisolone, she developed hepatic failure. On the 45th day, a liver transplant was performed. The second patient, a 54-year old RA patient, was diagnosed with autoimmune hepatitis after 12 infliximab infusions. She fulfilled autoimmune hepatitis type 1 criteria. A liver biopsy disclosed an altered lobulillar structure with chronic inflammation and the formation of collagen bands. She was treated with prednisolone and azatioprine and a complete recovery was noted 1 month later. These cases should alert rheumatologists to the possibility of new adverse reactions (liver injury) associated with the use of TNFα blockers in an autoimmune setting.
References
Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse–human chimeric anti-TNF antibody. Mol Immunol 30:1443–1453
Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Eng J Med 340:1398–1405
Lipsky PE, van de Heijde DMFM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Eng J Med 343:1594–1602
Saleem G, Li Shuan, MacPherson BR et al (2001) Hepatitis with interfase inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on article by Charles et al. Arthritis Rheum 44:1966–1968
Menghini V, Arora A (2001) Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 76:84–86
Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, Valesini G (2005) Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64:1519–1520
Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD (2004) Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 63:156–161
Diehl AM (2000) Cytokines regulation of liver injury and repair. Immunol Rev 174:160–171
Jarret S, Cunnane G, Conaghan P et al (2003) Anti-tumor necrosis factor-α therapy-induced vasculitis: case series. J Rheumatol 30:2287–2291
Debandt M, Vittecoq O, Descamps V et al (2003) Anti-TNF-α- induced systemic lupus syndrome. Clin Rheumatol 22:56–61
Robinson WH, Genovese MC, Moreand LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor alfa antagonism. Arthritis Rheum 44:1977–1983
Bloom BJ (2000) Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 46:2606–2608
Stratigos AJ, Antoniou C, Stamathioudaki S et al (2004) Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol 29:150–153
Foeldvari I, Krüger E, Schneider T (2003) Acute, non-obstructive, sterile cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis. Ann Rheum Dis 62:908–909
Pisetsky DS (2000) Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 43:2381–2382
Diamantis I, Boumpas DT (2004) Autoimmune hepatitis: evolving concepts. Autoimmun Rev 3:207–214
Vergani D, Mieli-Vergani G (2003) Autoimmune hepatitis. Autoimmun Rev 2:241–247
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tobon, G.J., Cañas, C., Jaller, JJ. et al. Serious liver disease induced by infliximab. Clin Rheumatol 26, 578–581 (2007). https://doi.org/10.1007/s10067-005-0169-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0169-y